Search

The South Asian Hub for Advocacy, Research and Education (SHARE) was a five-year National Institute of Mental Health (NIMH)-funded program that aimed to stimulate the research base for task-shifting mental health interventions to address the mental health treatment gap in low and middle-income countries. During its 5 years (2011-2016) SHARE made notable accomplishments, including providing 20 studentships for short courses and ten fellowships to conduct mentored study, developing a new humanitarian research training course, implementing distance learning courses, creating an online repository of training materials, creation of a network of public health researchers at different career stages in South Asia, strengthening of partnerships amongst institutions of SHARE network and supporting its member's to produce peer reviewed publications. Furthermore, additional research capacity building and research grants leveraged on SHARE network were secured. The salient lessons learned in the 5-year program were that research capacity-building opportunities need to be tailored to the local context, as SHARE sought to develop and support courses that can build the capacities in specific areas identified as weak in the South Asian region. Mentoring was recognized as a critical component for which innovative and effective models of mentoring in the region need to be developed. Diverse platforms and mediums ought to be utilized to deliver the research training programs. Finally, research capacity-building program requires collaborative efforts of multiple stakeholders working locally, nationally and globally to attain the maximum impact in a region. [ABSTRACT FROM AUTHOR]

The article presents a study which analyzes the variations and trends of atmospheric aerosol over South Asia based on MODIS observations. The study examined aerosol load over south Asia using Terra-MODIS AOD data from 2000 to 2009. Results show increasing trend of 10.17% in the aerosol optical depth (AO) but decrease in AOD is attributed to weakness of dust activity in the northwest India.

Background Treatment of non-small cell lung cancer (NSCLC) has undergone a paradigm shift in the last decade with the advent of targeted therapy and immunotherapy. Anaplastic Lymphoma Kinase (ALK) rearrangement and Programmed Death-Ligand 1 (PD-L1) expression are important predictive biomarkers for response to targeted therapy and immunotherapy respectively. How these two biomarkers interplay with each other is yet to be determined. Various studies have tried to establish a relationship between PD-L1 expression in tumors and treatment outcomes in ALK rearranged NSCLC, with conflicting results. There is a paucity of data regarding this relationship from the Indian subcontinent. Methods PD-L1 expression was assessed in tissue samples of 58 patients with advanced ALK rearranged NSCLC treated between 2015 and 2018. PD-L1 expression was measured by immunohistochemistry using VENTANA PD-L1 (SP263) antibody on formalin-fixed paraffin-embedded specimens. The epidemiological profile of patients and the relationship between progression free survival (PFS) on small molecule ALK inhibitor and PD-L1 expression were noted. Results The median age was 47 years (range 25-72 years) and there were 25 males (50%). Most of the patients were never smokers (88%). Thirty-seven (63.7%) of tumors expressed PD-L1 (≥1%) and 13 (22.4%) tumors had a PD-L1 expression of ≥ 50%. All of the patients received crizotinib as first line ALK inhibitor. Of the 44 patients evaluable for treatment response there was no significant difference in PFS between PDL1 negative cohort (median PFS - 13.8 months, CI 6.2-21.3 months) and PDL1 positive cohort (median PFS 10.9 months, CI 6.5-15.2 months, P-0.81). No association was seen between PD-L1 expression and PFS when PD-L1 expression levels were stratified by median or quartiles. In the subgroup analysis, PFS was not significantly different between different patterns of PDL1 expression or intensity of staining. Conclusions In contrast to previous studies, we found a higher incidence of PD-L1 expression in patients with ALK rearranged advanced NSCLC. PFS on ALK inhibitors did not differ based on PD-L1 expression. However, this was a retrospective study in a limited number of patients. More prospective studies are needed to confirm our findings. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest. [ABSTRACT FROM AUTHOR]